Medtide Inc., a joint stock company incorporated in the People's Republic of China, has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation Plan. This regulatory acceptance pertains to the conversion of 68,201,112 unlisted shares into H shares, each with a par value of RMB1.0. This development is a significant step towards the proposed implementation of the full circulation of H shares for certain shareholders of the company. The conversion and listing process will still require adherence to additional procedures mandated by the CSRC, the Hong Kong Stock Exchange, and other relevant regulatory authorities. Medtide Inc. has advised shareholders and potential investors to exercise caution when dealing in the company's securities. Further announcements will be made as details of the conversion and listing are finalized.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.